

血液内科学研究分野 (原研内科)

論文

A 欧文

A-a

- 1 . Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y: Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT. *Ann Hematol* 103(1): 307-320, 2024. doi: 10.1007/s00277-023-05527-5. *
- 2 . Konuma T, Itonaga H, Shimomura Y, Fujioka M, Aoki K, Uchida N, Onizuka M, Jinguji A, Tanaka M, Ueda Y, Katayama Y, Sawa M, Tanaka H, Nakamae H, Kawakita T, Maruyama Y, Takahashi S, Ishimaru F, Kanda J, Ichinohe T, Atsuta Y : Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy. *Hematol Oncol* 42(1): e3217, 2024. doi: 10.1002/hon.3217. *
- 3 . Setoguchi A, Kawano H, Okano S, Honda T, Kato T, Dateki S, Senoo A, Nakashima Y, Motokawa T, Ueno Y, Akashi R, Yonekura T, Sueyoshi E, Ikeda S, Miyazaki Y, Maemura K: An Iron-chelating Agent Improved the Cardiac Function in a Patient with Severe Heart Failure Due to Hereditary Hemochromatosis. *Intern Med* 63(2): 253-258,2024. doi: 10.2169/internalmedicine.1809-23. *
- 4 . Ogawa S, Sakamoto T, Matsuoka R, Ishitsuka K, Ogino Y, Sootome A, Makishima K, Yoshida C, Ito Y, Shimizu S, Suyama T, Shinagawa A, Ito T, Obara N, Kusakabe M, Sakata-Yanagimoto M, Miyazaki Y, Nannya Y, Chiba S: Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine. *Cancer Rep (Hoboken)* 7(1): e1938, 2024. doi: 10.1002/cnr2.1938. *
- 5 . Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y: Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). *Int J Hematol* 119(1): 24-38, 2024. doi: 10.1007/s12185-023-03677-w. *
- 6 . Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertzman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U: Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Haematol* 11(1): e38-e50, 2024. doi: 10.1016/S2352-3026(23)00333-2. *
- 7 . Nakashima M, Tanaka Y, Okamura H, Kato T, Imaizumi Y, Nagai K, Miyazaki Y, Murota H: Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma. *Cells* 13(2): 128,2024. doi: 10.3390/cells13020128. ○ *
- 8 . Itonaga H, Kato T, Sawayama Y, Katsuoka S, Furumoto T, Matsumoto N, Sasaki D, Yamada Y, Hashimoto M, Fujioka M, Sakamoto H, Hasegawa H, Imaizumi Y, Nagai K, Yanagihara K, Miyazaki Y: RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL. *Leuk Lymphoma* 65(2): 275-278, 2024. doi: 10.1080/10428194.2023.2276058. *
- 9 . Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H: Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). *Int J Hematol* 119(2): 130-145, 2024. doi: 10.1007/s12185-023-03686-9. *
- 10 . Shimasaki Y, Miyoshi H, Kawamoto K, Yoshida N, Mishina T, Nakashima K, Imamoto T, Sugio T, Yanagida E, Kato T, Yamada K, Takeuchi M, Suzuki T, Moritsubo M, Furuta T, Imaizumi Y, Takizawa J, Kato K, Suzumiya J, Suzuki R, Ohshima K : Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients. *Cancer Med* 13(3): e6793, 2024. doi: 10.1002/cam4.6793. *
- 11 . Okuda R, Ochi Y, Saiki R, Yamanaka T, Terao C, Yoshizato T, Nakagawa MM, Zhao L, Ohyashiki K, Hiramoto N, Sanada M, Handa H, Kasahara S, Miyazaki Y, Sezaki N, Shih LY, Kern W, Kanemura N, Kitano T, Imashuku S, Watanabe M, Creignou M, Chonabayashi K, Usuki K, Ishikawa T, Gotoh A, Atsuta Y, Shiraishi Y, Mitani K, Chiba S, Takaori-Kondo A, Miyano S, Kamatani Y, Haferlach T, Hellström-Lindberg E, Matsuda K, Yoshida Y, Makishima H, Nannya Y, Ogawa S: Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10). *Leukemia* 39(3): 760-764, 2024. doi: 10.1038/s41375-024-02494-2. ○ *
- 12 . Roboz GJ, Sanz GF, Griffiths EA, Yee KWL, Kantarjian HM, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illes A, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell C, Hao Y, Keer HN, Azab M, Döhner H : Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. *Blood Adv* 8(8): 2020-2029,2024. doi: 10.1182/bloodadvances. 2023012062.

- 13 . Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group: Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. *Am J Hematol* 99(5): 806-815, 2024. doi: 10.1002/ajh.27237. *
- 14 . Maeda T, Matsuda A, Kanda J, Kawabata H, Ishikawa T, Tohyama K, Kitanaka A, Araseki K, Shimbo K, Hata T, Suzuki T, Kayano H, Usuki K, Shindo-Ueda M, Arima N, Nohgawa M, Ohta A, Chiba S, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A, Mitani K; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes: Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry. *Br J Haematol* 204(5): 2086-2096, 2024. doi: 10.1111/bjh.19323. *
- 15 . Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351: A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. *Int J Hematol* 119(6): 647-659, 2024. doi: 10.1007/s12185-024-03733-z. *
- 16 . Nagai K, Tomari N, Egawa S, Koga Y, Itonaga H, Imanishi D, Yoshida S, Kinoshita I, Miyazaki Y, Tanaka A: Feasibility evaluation of a blood rotation system for efficient blood product utilization in remote island settings. *Vox Sang* 119(6): 548-555, 2024. doi: 10.1111/vox.13626. *
- 17 . Itonaga H, Miyazaki Y, Fujioka M, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, Katayama Y, Ota S, Kawakita T, Kato J, Matsuoka KI, Eto T, Onizuka M, Ichinohe T, Atsuta Y, Ishiyama K: Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy. *Bone Marrow Transplant* 59(8): 1107-1117, 2024. doi: 10.1038/s41409-024-02297-0. *
- 18 . Katsuoka S, Itonaga H, Sawayama Y, Chiwata M, Watanabe H, Yamada Y, Fujioka M, Kato T, Sato S, Ando K, Tashiro M, Takazono T, Imaizumi Y, Izumikawa K, Yanagihara K, Mukae H, Miyazaki Y : Septic arthritis as breakthrough invasive fusariosis after cord blood transplantation. *Leuk Res Rep* 22: 100483, 2024. doi: 10.1016/j.lrr.2024.100483.
- 19 . Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y: Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. *Blood Adv* 8(20): 5237-5247, 2024. doi: 10.1182/bloodadvances.2024012655. *
- 20 . Miyamoto D, Matsuguma K, Nagai K, Miyoshi T, Hara T, Matsushima H, Soyama A, Ochiya T, Miyazaki Y, Eguchi S: Efficacy of chemically induced human hepatic progenitor cells from diseased liver against nonalcoholic steatohepatitis model. *J Hepatobiliary Pancreat Sci* 31(10): 697-704, 2024. doi: 10.1002/jhbp.12046. *
- 21 . Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG: International Consortium on Myelodysplastic Syndromes : Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. *Lancet Haematol* 11(11): e862-e872, 2024. doi: 10.1016/S2352-3026(24)00251-5.
- 22 . Döhner H, DiNardo CD, Wei AH, Löwenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A: Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. *Blood* 144(21): 2169-2173, 2024. doi: 10.1182/blood.2024025409. *
- 23 . Itonaga H, Fukushima T, Kato K, Nakano N, Kato T, Tanaka T, Eto T, Mori Y, Kawakita T, Uchida N, Fujioka M, Nakamae H, Ogata M, Morishima S, Fukuda T, Kanda Y, Atsuta Y, Fuji S, Yoshimitsu M: Allogeneic transplantation for adult T-cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy. *Hematol Oncol* 42(6): e3315, 2024. doi: 10.1002/hon.3315. *
- 24 . Kobayashi Y, Ando K, Imaizumi Y, Sakamoto H, Kitanoosono H, Taguchi M, Mishima H, Kinoshita A, Bekytbek S, Baba M, Kato T, Horai M, Itonaga H, Sato S, Yoshiura S, Miyazaki Y: RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma. *Leuk Lymphoma* 65(12): 2116-2128, 2024. doi: 10.1080/10428194.2024.2393258. ○◇*
- 25 . Hashimoto M, Kato T, Yokota K, Sakamoto H, Horai M, Taguchi M, Itonaga H, Sato S, Baba M, Ando K, Imaizumi Y, Miyazaki Y: Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy. *Int J Hematol* 120(6): 694-704, 2024. doi: 10.1007/s12185-024-03857-2. ○*

- 26 . Yamada Y, Miyoshi H, Takeuchi M, Nakashima K, Yamada K, Kato T, Tanaka K, Kohno K, Imaizumi Y, Miyazaki Y, Ohshima K: TIGIT expression on neoplastic cells is a poor prognostic factor for adult T-cell leukaemia/lymphoma. *Pathology* 56(7): 993-999, 2024. doi: 10.1016/j.pathol.2024.06.003. ○*

A-c-1

- 1 . Zeidner JF, Yuda J, Watts JM, Levis MJ, Erba HP, Fukushima K, Shima T, Palmisiano ND, Wang ES, Borate U, Brandwein J, Papayannidis C, Montesinos P, Keiffer G, Miyazaki Y, Hosono N, Ikezoe T, Ogawa Y, Pardee TS, Strickland SA, Onodera K, Wu S, Ooi MG, Raffoux E, Vives S, Eghtedar A, Cai H, Allred C, Xu B, Robson P, Watanabe A, Hitron M, Shah J, Kantarjian HM, Daver N: Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia. *Blood* 144(Suppl 1): 213-216,2024. doi: 10.1182/blood-2024-194827.
- 2 . Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho GM, Gondek LP, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski J, Ogawa S: A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia. *Blood* 144(Suppl 1): 1332-1334,2024. doi: 10.1182/blood-2024-194024.
- 3 . Imai C, Hatta Y, Sato A, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito MA, Manabe A, Miyazaki Y, Matsumura I, Koh K, Kiyoi H, Horibe K: Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children's Cancer Group and Japan Adult Leukemia Study Group. *Blood* 144(Suppl 1): 1426-1427, 2024. doi: 10.1182/ blood-2024-199500.
- 4 . Fukuhara N, Maruyama D, Ishizawa K, Sano Y, Machida R, Makita S, Munakata W, Ichikawa S, Aizawa K, Miyazaki K, Kameoka Y, Rai S, Yagi Y, Takahashi N, Mushino T, Kato T, Miyazawa Y, Saito T, Shimada K, Kuroda J, Uryu H, Mishima Y, Takayama N, Suzuki Y, Uchida T, Nakamura N, Tabayashi T, Minami Y, Dobashi N, Tsukasaki K, Nagai H: Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study. *Blood* 144(Suppl 1): 338-340, 2024. doi: 10.1182/blood-2024-199868.
- 5 . Hatta Y, Hayakawa F, Yamazaki E, Murayama T, Saito T, Tanaka M, Doki N, Nishida T, Katsuoka Y, Takada S, Sakamoto T, Sato S, Atsuta Y, Ohtake S, Sakaida E, Maeda Y, Yamauchi T, Matsumura I, Miyazaki Y, Kiyoi H: JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults. *Blood* 144(Suppl 1): 2819-2821, 2024. doi: doi.org/10.1182/blood-2024-199435.
- 6 . Okuda R, Yotaro Ochi Y, Yoshizato T, Nannya Y, Atsuta Y, Shiraishi Y, Shiozawa Y, Tanaka H, Onizuka M, Chiba K, Itonaga H, Kanda Y, Miyazaki Y, Horibe K, Miyano S, Makishima H, Ogawa S: Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes. *Blood* 144(Suppl 1): 3203-3204, 2024. doi: 10.1182/blood-2024-206498.
- 7 . Suzuki K, Miyazaki K, Asano N, Takahashi H, Hiramoto N, Tatetsu H, Choi I, Arima H, Uchida T, Maruyama D, Kato T, Hiraga J, Kanemura N, Murayama T, Yano S, Ito S, Takahashi N, Iida S, Kobayashi T, Takao M, Tawara I, Yamaguchi M: Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan. *Blood* 144(Suppl 1): 3030-3032, 2024. doi: 10.1182/blood-2024-198992.
- 8 . Itonaga H, Miyazaki Y, Kondo T, Shimazu Y, Aoki J, Kurosawa S, Ikeda T, Eto T, Uchida N, Nakazawa H, Kawamura K, Kanda J, Atsuta Y, Tachibana T: Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia. *Blood* 144(Suppl 1): 4548-4549, 2024. doi: 10.1182/blood-2024-193697.
- 9 . Itonaga H, Miyazaki Y, Fujioka M, Kurosawa S, Nagata Y, Shimazu Y, Ueda T, Uchida N, Doki N, Nishida T, Matsuoka K, Tanaka M, Yoshimitsu M: Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity. *Blood* 144(Suppl 1): 6755-6756, 2024. doi: 10.1182/blood-2024-193699.
- 10 . Ando K, Miyazaki Y : Myelodysplastic syndromes among atomic bomb survivors in Nagasaki: similarities to and differences from de novo and therapy-related cases. *J Radiat Res* 65(Suppl 1): i88-i96, 2024. doi: 10.1093/jrr/rrae003.

B 邦文

B-a

- 1 . 川副靖晃, 石井浩二, 小松祐也, 坂本 光, 原 哲也: 硬膜穿刺後頭痛に対しプレガバリンが著効し,その後の繰り返し腰椎穿刺に対し穿刺針の変更及びプレガバリンの内服継続により頭痛の発症を予防できた1例. *日本臨床麻酔学会誌* 44(3): 290-294, 2024.
- 2 . 安東恒史, 古本嵩史, 宮崎泰司: 長崎における骨髓異形成症候群の疫学調査に基づく原爆被爆者に発症した骨髓異形成症候群の臨床像の解析. *長崎医学会雑誌* 99(特集): 211-214, 2024.

B-b

- 1 . 安東恒史, 宮崎泰司: [解説] 高リスクMDSに対するIWG奏功基準. *血液内科* 88(2): 201-206, 2024.
- 2 . 馬場真紀, 桐野祐子, 宮崎泰司: 骨髓系の腫瘍 骨髓異形成症候群 治療関連骨髓異形成症候群. *日本臨床 別冊血液症候群Ⅳ* : 137-140, 2024.

3. 蓬萊真喜子, 波多智子, 宮崎泰司: 骨髓系の腫瘍 白血病と類縁疾患 急性骨髄性白血病 急性赤白血病. 日本臨床別冊血液症候群Ⅳ: 179-182, 2024.
4. 児嶋 梓, 坂本 光, 宮崎泰司: 骨髓系の腫瘍 白血病と類縁疾患 急性骨髄性白血病 急性巨核芽球性白血病. 日本臨床別冊血液症候群Ⅳ: 183-186, 2024.
5. 安東恒史: 成人急性骨髄性白血病に対する最新の治療指針. 日本内科学会雑誌 113(7): 1235-1240, 2024.
6. 宮崎泰司: 白血病の分類の変遷. 臨床雑誌 内科 134(4): 839-844, 2024.
7. 安東恒史, 宮崎泰司: 骨髓異形成症候群の病型分類. CURRENT THERAPY 42(12): 1003-1015, 2024.
8. 桐野祐子, 宮崎泰司: [特集 白血病治療の最前線]薬物療法ー抗がん剤から分子標的薬へー 骨髓異形成症候群. 臨床と研究 101(12): 1483-1487, 2024.

B-c

1. 宮崎泰司: 急性骨髄性白血病. 今日の治療指針 2024年版 (Volume66): 677-680, 2024.
2. 宮崎泰司: IX 白血病系疾患: 腫瘍性疾患 9 治療関連骨髄性腫瘍. 血液専門医テキスト (改訂第4版): 286-289, 2024.
3. 安東恒史: I. 赤血球系疾患 11. 高リスクMDSに対する治療. EBM血液疾患の治療2025-2026: 59-64, 2024.
4. 宮崎泰司: 4節 骨髓異形成症候群 はじめに. WHO分類第5版による 白血病・リンパ系腫瘍の病態学: 65-68, 2024.
5. 宮崎泰司: 4節 骨髓異形成症候群 特定の遺伝子異常を有する骨髓異形成症候群. WHO分類第5版による 白血病・リンパ系腫瘍の病態学: 69-75, 2024.
6. 宮崎泰司: 4節 骨髓異形成症候群 形態により定義された骨髓異形成症候群. WHO分類第5版による 白血病・リンパ系腫瘍の病態学: 76-84, 2024.

B-c-1

1. 中島真帆, 竹中 基, 加藤丈晴, 宮崎泰司, 室田浩之: 当院でランダム皮膚生検を行ったintravascular large B-cell lymphomaのまとめ. 西日本皮膚科 86(2): 188-189, 2024.
2. 小谷龍太郎, 榊 智佳, 西村紗央里, 小林裕児, 三浦史郎, 伊東正博, 今泉芳孝, 吉田真一郎: 血小板増多症で発症しG分染法でフィラデルフィア染色体が検出されなかった慢性骨髄性白血病. 臨床血液 65(5): 439, 2024.
3. 松本和幸, 加藤丈晴, 桐野祐子, 児嶋 梓, 古本嵩文, 渡辺春香, 山田悠一, 橋本美紀, 坂本 光, 田口正剛, 蓬萊真喜子, 糸永英弘, 佐藤信也, 馬場真紀, 安東恒史, 三好寛明, 大島孝一, 宮崎泰司: 関節リウマチに対するタクロリムスの長期投与後に発症した他の医原性免疫不全リンパ増殖性疾患. 臨床血液 65(5): 443, 2024.
4. 朴 崇娟, 江口克秀, 石村匡崇, 蓬萊真喜子, 檜原直起, 木下恵志郎, 園田素史, 江口 緑, 小田義直, 宮崎泰司, 大賀正一: 末梢性T細胞リンパ腫の表現型を呈した遅発型Perforin欠損症の1例. 臨床血液 65(5): 444-445, 2024.
5. 勝岡真一, 今西大介, 加藤丈晴, 長置健司, 竹島史直, 大島孝一, 宮崎泰司: Pola+R-CHOP療法の経過中に乳び腹水を認めた高悪性度B細胞リンパ腫. 臨床血液 65(5): 448, 2024.
6. 児嶋 梓, 加藤丈晴, 山田悠一, 坂本 光, 蓬萊真喜子, 田口正剛, 佐藤信也, 馬場真紀, 安東恒史, 三好寛明, 大島孝一, 鈴宮淳司, 宮崎泰司: Ibrutinib治療中に再生不良性貧血様の病態を合併した慢性リンパ性白血病. 日本リンパ網内系学会誌 64(Suppl): 95, 2024.
7. 森 紗耶香, 佐々木大介, 吉瀬礼香, 大塩美央, 鶴田一人, 佐藤信也, 安東恒史, 長谷川寛雄, 宮崎泰司, 柳原克紀: 診断に苦慮したCCR4院生の成人T細胞白血病／リンパ腫 (ATLL) の1例. 日本検査血液学会雑誌 25(学術集会): S195, 2024.
8. 伊藤雅文, 宮崎泰司: 骨髄性／リンパ性腫瘍～血球形態と骨髓病理から始まる病態の理解～. 日本検査血液学会雑誌 25(学術集会): S225, 2024.
9. 中牟田瑠璃, 市来 澤, 竹中 基, 室田浩之, 一ノ宮 愛, 加藤丈晴, 一瀬将広, 蓬萊真喜子, 宮崎泰司, 添田李子, 上木 望: 視野障害を生じたDiffuse large B-cell lymphomaの1例. 西日本皮膚科 86(3): 318, 2024.
10. 森 紗耶香, 鶴田一人, 山内俊輔, 大久保翔貴, 中原萌衣, 吉村麻衣, 加藤丈晴, 長谷川寛雄, 宮崎泰司, 柳原克紀: 形態からの推測と異なりフローサイトメトリー検査が多発性骨髄腫の診断につながった1例. Cytometry Research 34(Suppl): 69, 2024.
11. 中島真帆, 小池雄太, 田中義正, 加藤丈晴, 宮崎泰司, 室田浩之: アレルギー反応・免疫応答 成人T細胞白血病リンパ腫患者の末梢血γδT細胞減少に伴う2型炎症の抑制. アレルギー 73(6-7): 866, 2024.
12. 中崎久美, 竹崎俊晶, 正本庸介, 小林幸夫, 宮崎泰司, 三谷絹子, 黒川峰夫: 改訂IPSS中間リスク群MDSにおけるフェリチン値の意義 全国多施設共同後方視的研究. 国際医療福祉大学学会誌 29(抄録): 180, 2024.

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2024	26	0	0	0	10	36	22	2	8	6	0	12	28	64

学会発表数一覧

	A-a	A-b シンポジウム	A-b 学会	合計	B-a	B-b シンポジウム	B-b 学会	合計	総計
2024	1	2	9	12	1	2	32	35	47

論文総数に係る教員生産係数一覧

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2024	0.563	4.000	0.611	2.444